Predictive biomarkers in the treatment of metastatic prostate cancer
Prostate cancer (PC) is among the top five deadliest cancers worldwide. In recent years, several new options for the treatment of metastatic PC have been approved, providing additional therapeutic choices. However, not all patients respond to the treatments, and most of them eventually develop resistance. There is an urgent need for predictive biomarkers to assist in optimal treatment selection, allowing timely changes in the treatment of non-responding patients. The EU-funded PDX-PC project aims to elucidate the molecular mechanisms responsible for tumour cell plasticity associated with treatment response in cases of metastatic PC. Researchers will employ patient-derived xenografts as in vivo models and genomics analysis to understand the molecular evolution of the disease, which will allow them to design more specific and individualised treatments in the future.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeMSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
See on map